Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 36, 2048-2052, June 1, 1976]
© 1976 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Forger, J. M.
Right arrow Articles by Cerny, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Forger, J. M., III
Right arrow Articles by Cerny, J.

Thymic Hormone Modulation of Leukemogenic Virus Replication1

John M. Forger, III2 and Jan Cerny

Department of Microbiology, Harvard School of Public Health, Boston, Massachusetts 02115

The effect of purified calf thymus extract, thymosin, on infection with murine leukemia virus (MuLV) (Rauscher) was studied in adult thymectomized BALB/c mice. The course of infection was determined by virus titer in the blood plasma, by enumeration of spleen cells replicating MuLV (i.e., infectious centers), and by the examination of cells for expression of virus-induced cell membrane antigen. Thymectomy (performed 1 week prior to the virus injection) decreased MuLV infection by all three parameters. However, administration of thymosin (500 µg, given in equal doses 2 days before and at the time of injection of virus) caused a marked increase of plasma titer of virus, as well as an increased number of spleen cells generating MuLV as compared to controls treated either with purified spleen fraction or with diluent (buffered salt solution). More than two doses of thymic extract (up to nine, given every 2 days after infection) had no further effect on plasma virus titer or number of splenic infectious centers. Furthermore, treatment of mice with either thymic or splenic extracts increased the incidence of virus-related membrane antigen appearing on the surface of spleen cells, as compared to diluent-treated control animals. These results indicate that thymosin may enhance infection by or replication of murine oncornaviruses.

1 This work was supported by the American Cancer Society and USPHS Grants CA-15277 and CA-14922.

2 Supported by USPHS Training Grant 2 T01 AI 000 14-17.

Received 1/ 9/76. Accepted 2/25/76.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1976 by the American Association for Cancer Research.